Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Dow Inc | 1,590 |
| 2 | Merck and Co Inc | 1,315 |
| 3 | 3M Co | 870 |
| 4 | Novartis AG | 625 |
| 5 | Bayer AG | 601 |
| 6 | Johnson and Johnson | 535 |
| 7 | Callaway Golf Co | 325 |
| 8 | Vertex Pharmaceuticals Inc | 262 |
| 9 | Organon and Co | 226 |
| 10 | Abbott Laboratories | 195 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 11,324 |
| 2 | A61K | Medicinal preparations | 10,653 |
| 3 | C07D | Heterocyclic compounds | 5,706 |
| 4 | C08L | Polymer compositions (blends) | 2,960 |
| 5 | Y10T | Cross-reference (technical subjects) | 2,644 |
| 6 | B32B | Layered products | 2,031 |
| 7 | C07K | Peptides | 1,428 |
| 8 | C08J | Working-up of plastics | 1,226 |
| 9 | C12N | Microorganisms, enzymes | 1,220 |
| 10 | C08K | Polymer compositions (additives) | 1,170 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Method of preparing milrinone lactate | 2008 | 17 | |
| Preparation method for high-purity milrinone | 2015 | 15 | |
| Method for synthesising milrinone | 2013 | 11 | |
| Milrinone lactate injection and preparation method thereof | 2012 | 10 | |
| Milrinone sodium chloride injection and production thereof | 2005 | 10 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 37 |
| 2017 | 35 |
| 2018 | 39 |
| 2019 | 41 |
| 2020 | 42 |
| 2021 | 41 |
| 2022 | 45 |
| 2023 | 39 |
| 2024 | 27 |
| 2025 | 7 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Xun Cui | Yanbian University | 14 |
| 2 | Wilson S. Colucci | Brigham and Women's Hospital | 12 |
| 3 | André Denault | Montreal Heart Institute | 10 |
| 4 | Maura Floreani | University of Padua | 9 |
| 5 | Robert Cody | NewYork–Presbyterian Hospital | 9 |
| 6 | Timothy M. Hoffman | Nationwide Children's Hospital | 7 |
| 7 | Satyan Lakshminrusimha | University at Buffalo, State University of New York | 7 |
| 8 | Hanno Ulmer | Innsbruck Medical University | 7 |
| 9 | Simon Parlow | University of Ottawa | 6 |
| 10 | David M. Kaye | The Alfred Hospital | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure | 1991 | 2241 | Heart Failure Treatment and Management |
| Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure A Randomized Controlled Trial | 2002 | 1176 | Heart Failure Treatment and Management |
| cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action | 2010 | 1026 | Nitric Oxide and Endothelin Effects |
| Clinical features, diagnosis, and management of enterovirus 71 | 2010 | 837 | Viral Infections and Immunology Research |
| Efficacy and Safety of Milrinone in Preventing Low Cardiac Output Syndrome in Infants and Children After Corrective Surgery for Congenital Heart Disease | 2003 | 774 | Heart Failure Treatment and Management |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of milrinone?
Which companies have filed the most patents related to milrinone?
What are the most highly cited research papers on milrinone?
Who are the most prolific authors publishing on milrinone?
How has patent and publication activity on milrinone changed over time?